Company
ResMed
NYSE:RMD / ASX:RMD (CDIs)
Sleep/respiratory; GLP-1 screening beneficiary.
At a glance
- Listing
- NYSE:RMD / ASX:RMD (CDIs)
- Category
- Healthtech
- Headquarters
- San Diego (founded Sydney)
- Market cap
- ~US$27–28B
Thesis
Why it is in this universe
- Category
- Healthtech
- Market
- Australia
- Recent inflection
- Acquired Noctrix Health (Jun 2026).
- Services
- None recorded
- People tracked
- 2
Market data
Listing and scale
| Metric | Detail |
|---|---|
| Exchange | NYSE |
| Ticker | NYSE:RMD / ASX:RMD (CDIs) |
| Secondary listing | ASX |
| Market cap | ~US$27–28B |
| Status | Listed and trading |
Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.
Get in touch
Contact
- Address
- San Diego (founded Sydney)
- Website
- No site on file
- Phone
- No public number published
- No public address published
Offering
What it sells today
No commercial services are recorded for this company yet.
People
Who variis tracks here (2)
variis does not publish portraits of named individuals without a licence to do so.
Recent inflection
What moved lately
Acquired Noctrix Health (Jun 2026).
Common questions
- Why does variis track ResMed?
- Sleep/respiratory; GLP-1 screening beneficiary.
- Is ResMed publicly listed?
- Yes. It trades as NYSE:NYSE:RMD / ASX:RMD (CDIs). Market capitalisation is in the ~US$27–28B range, recorded as a dated snapshot rather than a live quote.
- Where is ResMed based?
- San Diego (founded Sydney)
- Is ResMed still trading?
- ResMed is recorded as actively trading.
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
No source is on file for this company yet. Treat everything above as unverified until one is.
Every entity profile on variis is sourced. Not investment advice.